Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 16, 2025. 

NeurologyLive® Friday 5 — May 16, 2025

The FDA approved Fujirebio's Lumipulse G p-tau217/β-Amyloid 1-42 Plasma Ratio as the first in vivo blood test for early Alzheimer’s detection, demonstrating high diagnostic accuracy with strong correlations to amyloid PET and CSF test results.

FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease

Markted as Brekiya, Amneal Pharmaceuticals’ newly approved therapy offers a self-administered version of dihydroergotamine mesylate for adults with migraine or cluster headache.

FDA Approves First Autoinjector Form of DHE for Acute Migraine and Cluster Headache

Targeting tau pathology in preclinical Alzheimer disease could benefit from recruiting individuals positive for both Aß and GFAP biomarkers, improving patient selection and cost effectiveness.

Plasma GFAP May Enrich Patient Selection, Reduce PET Scans Required for Alzheimer Trials

Videos

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

, has been with the team since September 2022. Follow her on Twitter 

The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]

Advancing ALS Through Gene Therapies, Early Intervention, and Multidisciplinary Care: Brian Lin, PhD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Seif Elbualy, MD, discusses his role at the Brain and Spine Symposium and shares insights on the future of interventional pain management, evolving techniques, and pharmaceutical innovation.

Overviewing 2025 Baptist Health Brain and Spine Symposium: Exploring New Options in Chronic Pain Management

The director of the Tuberous Sclerosis Program at Cleveland Clinic provided clinical commentary on a novel clustering analysis in TSC, revealing how phenotype-genotype insights can lead to more personalized treatment and surveillance.

NeuroVoices: Ajay Gupta, MD, on Phenotyping Tuberous Sclerosis Complex Into Disease Clusters

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Management of Insomnia in Female Patients  

An expert discusses the frontline management of insomnia in female patients.

Charlene Gamadelo, MD, provides an overview of insomnia and discusses the prevalence by race and gender, the variations in presentation of symptoms in patients, and the pathways involved in sleep wakefulness cycles.

Overview of Insomnia

A neurology expert describes why women experience insomnia at higher rates than men and how co-occurrence of insomnia with other medical conditions, including psychiatric disorders, can affect occurrence. 

Insomnia in Female Patients

An overview of the impact insomnia can have on female patient’s quality of life and how they communicate sleep disturbance concerns with health care professionals.

Quality of Life and Patient Communication Regarding Insomnia

An overview of the different roles of health care professionals in the management of female patients suffering from insomnia.

Managing Female Patients With Insomnia

Charlene Gamadelo, MD, provides an overview of commonly utilized insomnia treatment modalities in the treatment of female patients with insomnia.

Approach to Treating Female Patients With Insomnia

Charlene Gamadelo, MD, describes the different categories of FDA approved treatments for insomnia along with challenges associated with these treatments.

Challenges Associated With Insomnia Treatments

An overview of dual orexin receptor agonists (DORAs) therapy for the treatment of insomnia in female patients.

Insomnia Treatment: DORAs

Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.

Insomnia Treatment Selection: DORA

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

Clinical

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Challenges Associated With Insomnia Treatments

EP: 1.Overview of Insomnia

EP: 2.Insomnia in Female Patients

EP: 3.Quality of Life and Patient Communication Regarding Insomnia

EP: 4.Managing Female Patients With Insomnia

EP: 5.Approach to Treating Female Patients With Insomnia

EP: 6.Challenges Associated With Insomnia Treatments

EP: 7.Insomnia Treatment: DORAs

EP: 8.Insomnia Treatment Selection: DORA